QResearch Scientific Committee Meeting 02.11.20
Minutes

**Attending:** Julia Hippisley-Cox, Sarah Lay-Flurrie, Rebekah Burrow, Clare Bankhead, Franco De Crescenzo (observer), Paula Dhiman (observer) Clare Bankhead, Madhurima Bhadra (observer), Rebecca Harmston (observer), Claire Meadows (Minutes)

**Apologies:** Mike Walton, Rafael Perera, Stavros Petrou

**Chair:** Paul Aveyard

**1 Welcome and apologies**
A welcome was extended to our four observers, who are attending as a result of our recent recruitment drive for Committee members.

**2 Minutes and actions last meeting**
Due to time constraints in this meeting, CM will recirculate minutes for approval.

**CM**

**3 Matters arising**
RB and CM are working on gathering information for the new QResearch annual report.

**4 Members leaving the Committee – Sarah Lay-Flurrie, Duncan Young**
Duncan is leaving the Committee due to retirement and Sarah is leaving the department at the end of the year.

**5 Applications for discussion**

**OX39 – DELTA – integrated Diagnostic solution for Early detection of Oesophageal Cancer**
CI: Julia Hippisley-Cox
Lead reviewer: Paul Aveyard
Need to step out: Julia Hippisley-Cox

PA thinks the application is constructed well and he saw nothing he wanted to change or improve. He is happy to approve the application. No further comments from Committee.

**OX94 – Development and validation of a risk assessment tool to improve early detection of childhood, adolescent and young adult cancer**
CI: Defne Saatci
Lead reviewer: Clare Bankhead
Need to step out: Julia Hippisley-Cox

CB wondered whether it was appropriate to undertake a nested case control study to
derive items for a prediction role and then in the same data set use that to derive and validate using a cohort designed clinical prediction model. PD said she hadn’t seen this before but she feels comfortable with it because it’s a separate analysis, albeit on the same data set. She advises that the applicants look at the literature on this and refine the rationale for doing it and discuss the limitations of using the same cohort for this. The applicants also need to give consideration to how they are going to adjust for the temporal effect of the association of the predictors because it is a very young and developing cohort. Revise and resubmit.

**OX99 – A second wave of crisis in the NHS after the COVID-19 pandemic (fast-track)**
CI: Catia Nicodemo
Lead reviewers: Paul Aveyard, Andrea Roalfe
Need to step out: Julia Hippisley-Cox, Stavros Petrou

Previously revised and resubmitted. PA happy with the revision and has approved.

**OX129 – Development and validation of statistical learning models to predict breast cancer diagnosis and breast cancer mortality: a cohort study**
CI: Ashley Clift
Lead reviewer: Sarah Lay Flurrie
Need to step out: Julia Hippisley-Cox, Stavros Petrou

SLF confirmed that the protocol is well-written and the methods are largely appropriate. SLF would like clarification on how the applicants are defining their outcomes, and also how the applicants are defining invasive breast cancer. She would also like clarification on two other points relating to exclusions and competing risk models. She considers that these are minor points. PA would like to ask the applicants why they believe their model is better than other existing models. Revise and resubmit.

**OX54 – CCCC-UK: Characteristics of Chronic Hepatitis B associated with Cirrhosis and Cancer: analysis of a large UK primary care database (practice)**
CI: Cori Campbell
Lead reviewers: Paula Dhiman, Madhurima Bhadra
Need to step out: N/A

*This was a practice exercise for our observers to complete to assess their suitability for a permanent role on the Committee.

**OX85 – The effect of obesity on incidence and severity of COVID-19 (practice)**
CI: Nerys Astbury
Lead reviewer: Franco De Crescenzo, Rebecca Harmston
Need to step out: N/A

*This was also a practice exercise for our observers to complete to assess their suitability for a permanent role on the Committee.*
6. Applications to be aware of

OX29 – Maternal depression and anxiety disorders and child mental health outcomes
CI: Catia Nicodemo
Need to step out if discussed: Julia Hippisley-Cox
Progress: expecting resubmission by applicants

Reviewed by SP and RP. A revise and resubmit that will come back in for re-review.

OX125 – CoMPuTE: Complex Multimorbidity Phenotypes, Trends, and Endpoints
CI: Rafael Perera
Need to step out if discussed: Rafael Perera
Progress: seeking reviewers

JHC suggested this be sent round the Committee and discussed at the December meeting.

Plus two new applications likely to be submitted before our next meeting in December.

Amendments approved by deputy-chair via email for:

OX22 (amendment 1) – Dietary or weight loss advice for hypertension and diabetes in primary care
CI: Carmen Piernas Sanchez
Need to step out if discussed: N/A

OX54 (amendment 1) – CCCC-UK': Characteristics of Chronic Hepatitis B associated with Cirrhosis and Cancer: analysis of a large UK primary care database
CI: Cori Campbell
Need to step out if discussed: N/A

OX85 (amendment 1) – The effect of obesity on incidence and severity of COVID-19
CI: Nerys Astbury
Need to step out if discussed: Julia Hippisley-Cox, Paul Aveyard

OX86 (amendment 1) – Associations between COVID-19 infection, tobacco smoking and nicotine use, common respiratory conditions and inhaled corticosteroids: a prospective QResearch–Case Mix Programme data linkage study January–May 2020.
CI: Nicola Lindson
Need to step out if discussed: Julia Hippisley-Cox, Paul Aveyard

OX102 (amendments 1 and 2) – Quantifying the association between ethnicity and COVID-19 outcomes: a population-based study using QResearch linked databases
CI: Julia Hippisley-Cox
Need to step out if discussed: Julia Hippisley-Cox

RB clarified that there is a new process for amendment requests and this has been in operation over the past week or so and the listed applications have been part of this new procedure.

RB also reminded the Committee that whether amendments can be approved by the Chair or the Deputy Chair, or need to go to the whole committee, is defined by the Chair or the Deputy Chair of the Committee rather than the CPRD guidelines which CPRD are no longer using.
7 Questions from RB:

This agenda item includes questions that RB asks members to further define processes to assure the smooth running of the Committee.

*What training would members like that we could provide?*

*How should we allocate reviews with our new committee members and new review process?*

PA suggested that we allocate on a rota system which is fair, but also be mindful of areas of expertise that may suit different members of the Committee. JHC also suggested that if you are aware of COIs or other impediments carrying out a fair evaluation that members should get back to RB within 24 hours to confirm this.

The decision on whether reviews should be carried out by two experts and one lay member was in discussion. JHC advocates two reviewers for ease, though members can review in a pair if this is suitable and possible. RB is going to proceed with three reviewers and see if that works well. If not we can review the process.

RB requested that members and the observers get back to her on what training they would find useful in their roles on the Committee.

8 AOB

None

9 Date of next meeting

14th December 2020  1pm – 2.30pm